Use of Macrolides in Acute Chest Syndrome: A Multicenter Retrospective Study

NCT07037706 | Completed

• 1 other identifier: 0063_REANIMATION
• Study Type: observational
• Target: 250
• Locations: 1 country
• Sites: 1

Brief Summary

This study looks at whether using macrolide antibiotics is helpful and safe in treating acute chest syndrome, a serious complication in people with sickle cell disease. It reviews past cases from three hospitals where patients were treated in intensive care. The goal is to understand if macrolides make a difference, what germs are involved, how useful lab tests are, and how well patients tolerate these antibiotics.

Conditions

Sickle Cell Disease; Acute Chest Syndrome; Glucose-6-Phosphate Dehydrogenase Deficiency; Anti-Bacterial Agents; Macrolides

Outcome Measures

Primary Outcomes (1)

• Duration of mechanical ventilation (in days) among patients with ACS treated with empiric macrolides

  28 days

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of adult patients (aged 18 and older) with sickle cell disease who were diagnosed with acute chest syndrome (ACS) and required hospitalization in an intensive care unit (ICU). All selected patients must have received an empiric antibiotic treatment including a macrolide and undergone microbiological sampling (such as PCR multiplex, sputum culture, or urinary antigen testing for Legionella). Participants will be identified retrospectively from medical records across the three participating hospital centers over the study period.

You may qualify if:

• Adult patient (≥18 years old).
• Diagnosis of acute chest syndrome (ACS).
• Hospitalized in an intensive care unit (ICU).
• Microbiological sampling performed (e.g., multiplex PCR, sputum culture \[ECBC\], and/or Legionella urinary antigen test).
• Received empiric antibiotic therapy including a macrolide.

You may not qualify if:

• Minor patient (\<18 years old).
• Acute chest syndrome not requiring ICU admission.
• Acute chest syndrome without any attempt at microbiological documentation.

Sponsors & Collaborators

• Centre Hospitalier de Saint-Denis: lead

Study Sites (1)

France

Saint-Denis, France, France

Location

MeSH Terms

Conditions

Anemia, Sickle Cell; Acute Chest Syndrome; Glucosephosphate Dehydrogenase Deficiency

Condition Hierarchy (Ancestors)

Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemoglobinopathies; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Lung Diseases; Respiratory Tract Diseases; Respiration Disorders; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 11, 2025
• First Posted: June 25, 2025
• Study Start: June 1, 2023
• Primary Completion: June 1, 2024
• Study Completion: June 1, 2024
• Last Updated: June 25, 2025

Record last verified: 2025-06

Locations

FR (1)